BioPharm Insight to Host Webinar in Advance of American College of Cardiology Conference

Share Article

"Key Presentations at ACC: Top Two Medical Device Developments" Webinar to address innovations in interventional cardiology

BioPharm Insight, the leading provider of intelligence to the biotechnology, pharmaceutical and medical device industries, today announced a free educational webinar that will focus on two major material medical device developments in interventional cardiology: Edwards Lifesciences’ Sapien transcatheter aortic heart valve and Abiomed’s Impella 2.5 percutaneous cardiac assist device.

Webinar participants will hear a forward-looking analysis of the data to be presented at ACC. Dr. Kirk Garratt, Clinical Director of Interventional Cardiovascular Research at Lenox Hill Hospital, New York, will discuss the implications of groundbreaking data for these devices with Viral Gandhi, BioPharm Insight’s Senior Medical Device Journalist.

The discussion will focus on the Cohort A of Sapien's Partner trial, which compares the treatment of severe aortic stenosis patients at high surgical risk on the Sapien versus a traditional surgical valve. As reported by BioPharm Insight, positive data is expected in Cohort A, which will pave the path for this technology's uptake in high risk patients.

The Protect II trial, which evaluated the Impella 2.5 device against the intra-aortic balloon pump, failed to meet its primary endpoint of superiority. The full release of this data, which will greatly impact the adoption of this technology, will be presented at the meeting. The Protect II trial data will impact reimbursement, which is drawing CMS attention, as previously reported by BioPharm Insight.

The ACC Annual Scientific Session & Expo will be held in New Orleans from April 2-5.

Webinar Information:
Tuesday, March 15, 2011, 11:30 a.m. ET/8:30 a.m. PT
Register by clicking here: https://www2.gotomeeting.com/register/591994258
Registrants will receive our free “Interventional Cardiology Intelligence Report”

About Infinata & BioPharm Insight:
Infinata is a wholly-owned subsidiary of the Financial Times Group, publisher of the Financial Times newspaper and FT.com. Infinata’s life sciences suite of products: BioPharm Insight, BioPharm Devices and BioPharm Clinical provide a fully integrated information suite covering the data, search, networking, and intelligence needs of the Pharmaceutical, Biotech, CRO, Device and Medtech community. For product and sales information, visit: http://www.biopharminsight.com.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Liz Bearce